Clinical Research Directory

Inclusion Criteria: * Age ≥ 18 years, regardless of gender; * Patients with ST-segment elevation myocardial infarction (STEMI) (meeting the diagnostic criteria of the 2019 Chinese "Guidelines for the Diagnosis and Treatment of Acute ST-Segment Elevation Myocardial Infarction"); * Patients undergoing percutaneous coronary intervention (PCI); * Patients with slow flow after PCI (TIMI flow grade \> 0 but \< 3); * Signed informed consent form and willingness to comply with follow-up. Exclusion Criteria: * Presence of malignant tumors or diseases with a life expectancy of less than 1 year; * Coagulation disorders, diagnosed or suspected hematological diseases (excluding mild or moderate anemia); * Thrombocytopenia (platelet count \< 100 × 10⁹/L); history of severe gastrointestinal diseases or peptic ulcers; active bleeding within the past 3 months or major surgery history; history of intracranial hemorrhage or intracranial aneurysm; * History of cerebral hemorrhage or ischemic stroke within the past 6 months; * Patients with cardiogenic shock; systemic infections or immune system diseases; confirmed, highly suspected, or unable to rule out aortic dissection; severe uncontrolled hypertension (systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 110 mmHg); * Current use of rivaroxaban or requiring long-term anticoagulation therapy (e.g., atrial fibrillation); * Patients with renal insufficiency (eGFR \< 15 mL/min/1.73m²) or hepatic insufficiency (Child-Pugh Class B or C); * Lactating or pregnant women, or women of childbearing potential unable to use effective contraception during the study period; * Patients with any contraindications or allergies to rivaroxaban, aspirin, clopidogrel, or ticagrelor; * Participation in other clinical trials within the past 3 months; * Other conditions deemed unsuitable for participation by the investigator.